

Cordavis

Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
83457-0124-02	Humira (2 Pen) Subcutaneous Pen-injector Kit 80 MG/0.8ML	4/1/2024
83457-0243-02	Humira (2 Syringe) Subcutaneous Prefilled Syringe Kit 40 MG/0.4ML	4/1/2024
83457-0554-02	Humira (2 Pen) Subcutaneous Pen-injector Kit 40 MG/0.4ML	4/1/2024
83457-0616-02	Humira (2 Syringe) Subcutaneous Prefilled Syringe Kit 20 MG/0.2ML	4/1/2024

83457-0817-02	Humira (2 Syringe) Subcutaneous Prefilled Syringe Kit 10 MG/0.1ML	4/1/2024
---------------	---	----------

10 or 11 Digit NDC

This will include: Drug Trade Name,
Active Ingredient, Strength, and Size

Date Product was commercially
available

Key **Used for Full Report Due 30 Days After Initial Notice**

Submissions Made To AGO.highcostprescriptiondrugs@vermont.gov

WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
\$13,845.27	Cordavis Humira is being developed as a co-branded initiative. Humira exists on the market today under other manufacturer NDCs. Cordavis has no reportable marketing and/or advertising budget or plan associated with this NDC.	N
\$6,922.62	Cordavis Humira is being developed as a co-branded initiative. Humira exists on the market today under other manufacturer NDCs. Cordavis has no reportable marketing and/or advertising budget or plan associated with this NDC.	N
\$6,922.62	Cordavis Humira is being developed as a co-branded initiative. Humira exists on the market today under other manufacturer NDCs. Cordavis has no reportable marketing and/or advertising budget or plan associated with this NDC.	N
\$6,922.62	Cordavis Humira is being developed as a co-branded initiative. Humira exists on the market today under other manufacturer NDCs. Cordavis has no reportable marketing and/or advertising budget or plan associated with this NDC.	N

\$6,922.62	Cordavis Humira is being developed as a co-branded initiative. Humira exists on the market today under other manufacturer NDCs. Cordavis has no reportable marketing and/or advertising budget or plan associated with this NDC.	N
------------	--	---

WAC on the date the Product was commercially available

A narrative description of the marketing and pricing plans used in the launch of the new prescription drug in the United States and internationally

Please respond with Yes or No



ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
2158	N	N
3980	N	N
47487	N	N
454	N	N

0	N	N
---	---	---

The estimated number of patients in the United States with a condition for which the new prescription drug may be prescribed

Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
[REDACTED]		




If this field in N/A then please leave
blank

If this field in N/A then please leave
blank

Please respond with Yes or No



ACQUISITION PRICE COMMENT	GENERAL COMMENTS
[REDACTED]	
[REDACTED]	
[REDACTED]	
[REDACTED]	



If this field is N/A then please leave
blank

